atopic dermatitis

Biotech

Vyne to reevaluate pipeline after eczema fail uproots plans

Vyne’s lead asset has failed to improve the severity of atopic dermatitis, uprooting the biotech’s plans and sending the stock plummeting.
Gabrielle Masson Aug 10, 2022 11:23am

Amgen hits pause on $400M eczema bet to tweak phase 3 study

Aug 4, 2022 7:00am

Evelo Biosciences pauses dermatitis drug after trail failure

Apr 14, 2022 11:45am

Lilly’s $1B bet yields 'compelling' data on Dupixent rival

Mar 28, 2022 7:40am

J&J ends work on eczema drug, a $610M dent to ex-XBiotech asset

Feb 2, 2022 5:42pm

Novartis JAKs in rival to Incyte after seeing clinical data

Feb 2, 2022 7:30am